Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BIRC6 antisense RNA 2 is a conserved long non-coding RNA composed of several exons that overlaps the intronic region of the protein-coding BIRC6 gene in antisense orientation. It is expressed predominantly in the developing brain and eye, with knockout and knockdown experiments in zebrafish embryos resulting in defects in brain and eye development, including expanded brain ventricles and loss of specific neuron populations. Its mechanism of action is likely related to regulation of gene expression, either by modulating transcription or splicing of nearby genes such as BIRC6, but may also involve broader regulation via chromatin organization as is characteristic of many lncRNAs. There is no current evidence that BIRC6-AS2 serves as a therapeutic target, nor are there drugs or biomarkers in clinical use associated with its modulation.
Not applicable for direct drug interaction; the mechanism is believed to be regulation of gene expression through antisense transcript interactions, possibly by influencing splicing or chromatin organization on the BIRC6 locus
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BIRC6 antisense RNA 2 (BIRC6-AS2).